Synergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells via Modulation of ROS Generation and ERK1/2
Explore this paper's citation graph
Summary
The strategy of combining carfilzomib and LBH589 warrants attention in multiple myeloma, as the combined treatment synergistically increased mitochondrial injury, caspase activation, and apoptosis in MM cells.
- Type
- article
- Published
- 2015-04-27
- Cited by
- 26
- References
- 25
- Access
- Open access
- OpenAlex
- https://openalex.org/W2091268381
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:18916514
Keywords
Carfilzomib, Panobinostat, Apoptosis, Proteasome inhibitor, Oxidative stress
References
- The histone deacetylase inhibitor, PXD101, potentiates bortezomib‐induced anti‐multiple myeloma effect by induction of oxidative stress and DNA damage
- The cellular response to oxidative stress: influences of mitogen-activated protein kinase signalling pathways on cell survival.
- New Approaches to Management of Multiple Myeloma
- Histone Deacetylase Inhibitors Activate NF-κB in Human Leukemia Cells through an ATM/NEMO-related Pathway*
- The emerging role of carfilzomib combination therapy in the management of multiple myeloma
- Current and Emerging Treatment Options for Patients with Relapsed Myeloma
- Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma
- Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors.
- Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma.
- PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.
- Reactive Oxygen Species Generation and Mitochondrial Dysfunction in the Apoptotic Response to Bortezomib, a Novel Proteasome Inhibitor, in Human H460 Non-small Cell Lung Cancer Cells*
- Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy
- The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis
- Proteasome inhibitor carfilzomib interacts synergistically with histone deacetylase inhibitor vorinostat in Jurkat T-leukemia cells.
- Panobinostat in lymphoid and myeloid malignancies
- A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma
- CARFILZOMIB INTERACTS SYNERGISTICALY WITH HISTONE DEACETYLASE INHIBITORS IN MANTLE CELL LYMPHOMA CELLS IN VITRO AND IN VIVO
- Panobinostat for the treatment of multiple myeloma
- Synergistic Induction of Oxidative Injury and Apoptosis in Human Multiple Myeloma Cells by the Proteasome Inhibitor Bortezomib and Histone Deacetylase Inhibitors
- Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p53, PI3K/AKT, and NF-κB
Cited by
- Strategy for enhancing the therapeutic efficacy of histone deacetylase inhibitor dacinostat: the novel paradigm to tackle monotonous cancer chemoresistance
- Oxidative Stress and Proteasome Inhibitors in Multiple Myeloma
- Cyclin D1 unbalances the redox status controlling cell adhesion, migration, and drug resistance in myeloma cells
- Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors
- Histone deacetylase inhibitors in plasma cell leukemia treatment: effect of bone marrow microenvironment.
- Small molecule CP-31398 induces reactive oxygen species-dependent apoptosis in human multiple myeloma
- Investigating the mechanisms by which histone deacetylase inhibitors induce apoptosis in cancer cells
- The proteasome and proteasome inhibitors in multiple myeloma
- Synergistic anticancer effect of panobinostat and topoisomerase inhibitors through ROS generation and intrinsic apoptotic pathway induction in cervical cancer cells
- Metformin and FTY720 Synergistically Induce Apoptosis in Multiple Myeloma Cells
- The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease
- Inhibitory histondeacetyláz v léčbě plazmocelulární leukemie: vliv mikroprostředí kostní dřeně
- MPT0G612, a Novel HDAC6 Inhibitor, Induces Apoptosis and Suppresses IFN-γ-Induced Programmed Death-Ligand 1 in Human Colorectal Carcinoma Cells
- Role of HDACs in normal and malignant hematopoiesis
- Efficacy of Panobinostat for the Treatment of Multiple Myeloma
- Epigenetic targeting in lymphoma
- Novel Approaches to Epigenetic Therapies: From Drug Combinations to Epigenetic Editing
- Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma.
- Chidamide, a subtype-selective histone deacetylase inhibitor, enhances Bortezomib effects in multiple myeloma therapy
- Modulation of Cellular Redox Parameters for Improving Therapeutic Responses in Multiple Myeloma
Related papers
- Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma
- Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma
- Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
- Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial
- Abstract 1768: Chloroquine potentiates carfilzomib but not bortezomib effects on myeloma cells
- A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose‐expansion cohort
- Carfilzomib: A New Proteasome Inhibitor for Treatment of Multiple Myeloma
- Carfilzomib: Second proteasome inhibitor approved for multiple myeloma